Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Faricimab + PRP vs. Vitrectomy + Endolaser for PDR
NCT06790784Phase 3Recruiting
- Sponsor
- Jaeb Center for Health Research
- Start
- Aug 2025
- Primary completion
- Aug 2031
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of faricimab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Jaeb Center for Health Research. Primary endpoints: Visual Acuity Change from Baseline at 3 years and Number of Post-Randomization Treatments for Proliferative Diabetic Retinopathy at 3 years. Started Aug 2025; status: recruiting.
02
Drugs
faricimab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT06790784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790784.